GlassScriptPhysician profile
Naba Sharif
NPI 1164640892
$8,536.35
in general payments reported to CMS, 2019-2025
33 companies · $3,066 in 2025
The $3,066 reported for 2025 was more than what 76% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $715 · 2020: $562 · 2021: $1,177 · 2022: $854 · 2023: $1,279 · 2024: $885 · 2025: $3,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,596 · Consulting Fee: $1,479 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,595.82 |
| Consulting Fee | $1,479.12 |
| Education | $154.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,282.90 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,773.07 | 2019-2025 | Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $677.54 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $650.29 | 2019-2025 | Nucala, Trelegy Ellipta |
| Csl Behring | $336.91 | 2019-2025 | Andembry, Hizentra |
| Optinose US, INC. | $318.18 | 2020-2024 | |
| Genentech USA, INC. | $264.43 | 2019-2025 | Xolair |
| Alk-Abello, INC | $234.43 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Pfizer INC. | $220.00 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $219.50 | 2020-2025 | Takhzyro, Hyqvia, Aralast |
| Kaleo, INC. | $167.27 | 2019-2024 | Auvi-Q |
| Aimmune Therapeutics, INC. | $166.70 | 2020-2022 | |
| Amgen INC. | $161.29 | 2022-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $144.07 | 2023-2025 | |
| Grifols USA, LLC | $129.49 | 2023-2025 | Xembify |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $106.65 | 2021 | |
| Stryker Corporation | $94.36 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $91.92 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $78.37 | 2020-2024 | |
| Pharming Healthcare, INC. | $60.88 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $49.93 | 2025 | Orladeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.49 | 2021 | |
| Leo Pharma INC. | $42.03 | 2023-2024 | Adbry |
| Shire North American Group INC | $33.98 | 2019 | |
| Adma Biomanufacturing LLC | $33.12 | 2025 | |
| Ionis Pharmaceuticals, INC. | $32.37 | 2025 | Dawnzera |
| Abbvie INC. | $25.44 | 2023 | Skyrizi |
| Gc Biopharma USA, INC. | $19.95 | 2025 | Alyglo |
| Octapharma USA, INC. | $19.61 | 2023 | Cutaquig |
| Paratek Pharmaceuticals, INC. | $16.41 | 2025 | Xhance |
| Blueprint Medicines Corporation | $15.65 | 2025 | Ayvakit |
| Aytu Biopharma, INC. | $13.25 | 2020 | |
| Bio Products Laboratory USA, INC. | $12.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naba Sharif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.